Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome P-450 CYP2C9
Authors:
- José HermidaJHJosé Hermida
- Ramón MontesRMRamón Montes
- José Antonio PáramoJPJosé Antonio Páramo
- Eduardo RochaEREduardo Rocha
- José ZarzaJZJosé Zarza
- 1 January 2003
- journal article
- letter
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 90 (07) , 161-162
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin TherapyJAMA, 2002
- Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizersPharmacogenetics, 2001
- Managing Oral Anticoagulant TherapyChest, 2001
- Hemorrhagic Complications of Anticoagulant TreatmentChest, 2001
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999